Cislini Jeff 4

What Happened
Jeff Cislini, General Counsel of Revolution Medicines (RVMD), sold 908 shares in an open-market/private sale on January 21, 2026 at $115.60 per share, generating $104,965 in proceeds. The Form 4 indicates the sale was executed pursuant to a 10b5-1 trading plan adopted March 13, 2025. This was a disposition (sale), a routine liquidity event rather than a purchase.

Key Details

• Transaction date and price: 2026-01-21 — 908 shares at $115.60 each.
• Proceeds: $104,965.
• Filing date: 2026-01-23 — filed two business days after the trade (appears timely).
• Footnote: Sale was made under a 10b5-1 plan adopted March 13, 2025.
• Reported ownership: filing notes beneficial ownership includes 38,769 restricted stock units (RSUs). Total shares owned after the sale are not specified in the provided data.

Context

• Trades executed under 10b5-1 plans are pre-scheduled and commonly used for orderly selling; they are generally considered routine and not a definitive signal of insider sentiment.
• For retail investors, a one-off sale of 908 shares by a general counsel is modest; purchases typically carry more weight when inferring insider conviction.
• No option exercises, gifts, or tax-withholding dispositions are reported in the provided transaction details.